The University of Southampton
University of Southampton Institutional Repository

Nanoparticles-assisted delivery of antiviral-siRNA as inhalable treatment for human respiratory viruses: a candidate approach against SARS-COV-2

Nanoparticles-assisted delivery of antiviral-siRNA as inhalable treatment for human respiratory viruses: a candidate approach against SARS-COV-2
Nanoparticles-assisted delivery of antiviral-siRNA as inhalable treatment for human respiratory viruses: a candidate approach against SARS-COV-2
The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has challenged healthcare structures across the globe. Although a few therapies are approved by FDA, the search for better treatment options is continuously on rise. Clinical management includes infection prevention and supportive care such as supplemental oxygen and mechanical ventilatory support. Given the urgent nature of the pandemic and the number of companies and researchers developing COVID-19 related therapies, FDA has created an emergency program to move potential treatments with already approved drugs to patients as quickly as possible in parallel to the development of new drugs that must first pass the clinical trials. In this manuscript, we have reviewed the available literature on the use of sequence-specific degradation of viral genome using short-interfering RNA (siRNA) suggesting it as a possible treatment against SARS-CoV-2. Delivery of siRNA can be promoted by the use of FDA approved lipids, polymers or lipid-polymer hybrids. These nanoparticulate systems can be engineered to exhibit increased targetability and formulated as inhalable aerosols.
612-621
Ullah, Ata
25fbc91a-f745-485a-8384-fad9d015a079
Qazi, Javaria
bc4c46e7-c031-4163-a025-9ca8e377cffa
Kanaras, Antonios
667ecfdc-7647-4bd8-be03-a47bf32504c7
Khan, Waheed
3f0aec0a-e7a4-41c6-9f77-1b072988a106
Hussain, Irshad
29c18c0d-0009-490c-b6f8-506f3dfc2c69
Rehman, Asma
6f98130a-cefb-4638-ad9c-38cdf9ab078c
Ullah, Ata
25fbc91a-f745-485a-8384-fad9d015a079
Qazi, Javaria
bc4c46e7-c031-4163-a025-9ca8e377cffa
Kanaras, Antonios
667ecfdc-7647-4bd8-be03-a47bf32504c7
Khan, Waheed
3f0aec0a-e7a4-41c6-9f77-1b072988a106
Hussain, Irshad
29c18c0d-0009-490c-b6f8-506f3dfc2c69
Rehman, Asma
6f98130a-cefb-4638-ad9c-38cdf9ab078c

Ullah, Ata, Qazi, Javaria, Kanaras, Antonios, Khan, Waheed, Hussain, Irshad and Rehman, Asma (2020) Nanoparticles-assisted delivery of antiviral-siRNA as inhalable treatment for human respiratory viruses: a candidate approach against SARS-COV-2. Nano Select, 1 (6), 612-621, [6]. (doi:10.1002/nano.202000125).

Record type: Article

Abstract

The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has challenged healthcare structures across the globe. Although a few therapies are approved by FDA, the search for better treatment options is continuously on rise. Clinical management includes infection prevention and supportive care such as supplemental oxygen and mechanical ventilatory support. Given the urgent nature of the pandemic and the number of companies and researchers developing COVID-19 related therapies, FDA has created an emergency program to move potential treatments with already approved drugs to patients as quickly as possible in parallel to the development of new drugs that must first pass the clinical trials. In this manuscript, we have reviewed the available literature on the use of sequence-specific degradation of viral genome using short-interfering RNA (siRNA) suggesting it as a possible treatment against SARS-CoV-2. Delivery of siRNA can be promoted by the use of FDA approved lipids, polymers or lipid-polymer hybrids. These nanoparticulate systems can be engineered to exhibit increased targetability and formulated as inhalable aerosols.

Text
nano.202000125 - Version of Record
Available under License Creative Commons Attribution.
Download (1MB)

More information

Accepted/In Press date: 25 September 2020
Published date: 12 October 2020

Identifiers

Local EPrints ID: 451084
URI: http://eprints.soton.ac.uk/id/eprint/451084
PURE UUID: 295a68e2-207b-4abe-b3e2-1590c37be01b
ORCID for Antonios Kanaras: ORCID iD orcid.org/0000-0002-9847-6706

Catalogue record

Date deposited: 07 Sep 2021 16:32
Last modified: 08 Sep 2021 01:42

Export record

Altmetrics

Contributors

Author: Ata Ullah
Author: Javaria Qazi
Author: Waheed Khan
Author: Irshad Hussain
Author: Asma Rehman

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×